Jove
Visualize
Contact Us

Related Experiment Videos

Therapeutic needs revive arsenic compound.

Bradley

    Pharmaceutical Science & Technology Today
    |December 16, 2000
    PubMed
    Summary
    This summary is machine-generated.

    Arsenic trioxide, once an insecticide, is now approved to treat acute promyelocytic leukaemia (APL). This rare leukaemia affects about 2000 Americans annually, offering new hope for patients.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Diagnosis of Infantile Diseases.

    Buffalo medical and surgical journal·2023
    Same author

    An Account of the Publications and Experiments on the Cow-Pox; Illustrated by a Coloured Plate, Which Exhibits the Appearance of the Eruption on the Arm of a Milker on the Tenth Day of the Disease. The Pock on the Forefinger Represents the Appearance of a Vesicle before Suppuration Begins.

    The Medical and physical journal·2018
    Same author

    Observations on Hydrophobia.

    The Medical and physical journal·2018
    Same author

    Doped silica fibre thermoluminescence measurements of radiation dose in the use of <sup>223</sup>Ra.

    Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine·2017
    Same author

    Metalation of a 3,5-dichloro-teritary benzamide. An unusual regioselectivity observation

    The Journal of organic chemistry·2001
    Same author

    Parametric excitation of Alfven waves by gravitational radiation

    Physical review. E, Statistical physics, plasmas, fluids, and related interdisciplinary topics·2001
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies

    Area of Science:

    • Oncology
    • Hematology
    • Toxicology

    Background:

    • Arsenic compounds have historical uses, including as insecticides.
    • Acute promyelocytic leukaemia (APL) is a rare and aggressive subtype of leukaemia.
    • Limited treatment options previously existed for APL.

    Purpose of the Study:

    • To report the FDA approval of Trisenox (arsenic trioxide) for APL treatment.
    • To highlight the significance of this new therapeutic option for a rare cancer.

    Main Methods:

    • FDA review and approval process.
    • Clinical data supporting the efficacy and safety of arsenic trioxide in APL.

    Main Results:

    • Arsenic trioxide (Trisenox) approved by the FDA on September 26, 2000.

    Related Experiment Videos

  • Targeted treatment for acute promyelocytic leukaemia (APL).

    • Conclusions:

    • Arsenic trioxide represents a novel therapeutic agent for APL.
    • The approval provides a new treatment avenue for approximately 2000 APL patients in the USA annually.